[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$160billion
Tether's USDT stablecoin hits a record $XXX billion in circulation. The bispecific antibodies market is set to grow, with Genmab leading the charge.
About $160billion
Analysis of social media activity and market data related to the $XXX billion figure, likely referring to the market capitalization or value of a financial asset or entity.
Insights #
- $160billion creators is up XXX% from the previous month.
- $160billion mentions is up XXXXXX% from the previous month.
Engagements: X #
Engagements 24-Hour Chart Data
Current Value: X
Daily Average: XXXXX
1 Week: XXX -XX%
1 Month: XXXXXX +7,389%
1-Year High: XXXXXXX on 2025-05-20
1-Year Low: X on 2025-06-27
| Social Network | X |
|---|---|
| Engagements | X |
Mentions: X #
Mentions 24-Hour Chart Data
Current Value: X
Daily Average: X
1 Week: X +67%
1 Month: XX +233%
1-Year High: X on 2025-05-21
1-Year Low: X on 2025-04-29
| Social Network | X |
|---|---|
| Mentions | X |
Creators: X #
Creators 24-Hour Chart Data
X unique social accounts have posts mentioning $160billion in the last XX hours which is down XX% from X in the previous XX hours
Daily Average: X
1 Week: X +67%
1 Month: X +200%
1-Year High: X on 2025-05-21
1-Year Low: X on 2025-04-29
Top topics mentioned In the posts about $160billion in the last XX hours
$war, $160b, $20billion, $gmab, whitehouse, savings, $8billion
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Insurance coverage So if 200mil require a $XX shot X times a year. That is. $XXX times 200mil automation. let's see the amount. $20billion. a year. $XXX. $160billion. The point is coverage. Automated payout. thru a jab in arm. $160b plus countries that buy it. $war$"
@Creaturesxkb on X 2025-07-26 16:46:04 UTC XXX followers, X engagements
"The bispecific antibodies market is set to grow XX% annually reaching over $XXX billion by 2032 a huge upside for $GMAB Heres why it matters: X. Genmabs DuoBody platform drives epcoritamab a bispecific cancer therapy already on the market and expanding into new uses. X. They have a deep pipeline of late-stage bispecifics. X. Bispecific antibodies are transitioning from niche to mainstream in oncology and Genmab is leading the charge. Competition is growing but Genmab is well-positioned to benefit as one of the earliest and most advanced players. Learn more about the booming bispecific market"
@investseekers on X 2025-07-22 08:15:58 UTC 2656 followers, XXX engagements